Get the Stockscreener App
4.72
4.63%
-0.25
Adc Therapeutics SA stock is currently priced at $4.72, with a 24-hour trading volume of 120.62K.
It has seen a -4.63% decreased in the last 24 hours and a +4.41% rose in the past month.
The chart indicates a potential bearish trend, as the stock is below the $4.92 pivot point. If it approaches the $4.56 support level, significant changes may occur.
Previous Close:
$4.97
Open:
$4.99
24h Volume:
120.62K
Market Cap:
$410.17M
Revenue:
$69.56M
Net Income/Loss:
$-240.05M
P/E Ratio:
-2.0793
EPS:
-2.27
Net Cash Flow:
$-121.90M
1W Performance:
-4.44%
1M Performance:
+4.41%
6M Performance:
+567.42%
1Y Performance:
+141.84%
1D Range:
$4.71
$5.00
52W Range:
$0.3599
$6.04
Adc Therapeutics SA Stock (ADCT) Company Profile
Name
Adc Therapeutics SA
Sector
Industry
Phone
41 21 653 02 00
Address
Biopole, Route de la Corniche 3B, Epalinges
Adc Therapeutics SA Stock (ADCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Upgrade | JP Morgan | Underweight → Neutral |
| Apr-24-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-22 | Initiated | CapitalOne | Overweight |
| Nov-09-22 | Downgrade | BofA Securities | Buy → Neutral |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Sep-09-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Aug-17-21 | Resumed | Jefferies | Buy |
| Aug-09-21 | Initiated | RBC Capital Mkts | Outperform |
| Jun-15-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-20 | Initiated | Stifel | Hold |
| Oct-29-20 | Initiated | H.C. Wainwright | Buy |
| Jun-09-20 | Initiated | BofA/Merrill | Buy |
| Jun-09-20 | Initiated | Cowen | Outperform |
View All
Adc Therapeutics SA Stock (ADCT) Latest News
ADC Therapeutics meldet Updates zur klinischen Studie LOTIS-7. Diese untersucht ZYNLONTA® in Kombination mit Glofitamab oder Mosunetuzumab bei Patienten mit rezidiviertem/refraktärem B-Zell-Non-Hodgkin-Lymphom
GlobeNewswire Inc.
ADC Therapeutics Announces Updates on LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Glofitamab or Mosunetuzumab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
GlobeNewswire Inc.
ADC Therapeutics lädt am Dienstag, den 9. April 2024 zu einer virtuellen Konferenz für Forschungsinvestoren ein
GlobeNewswire Inc.
ADC Therapeutics to Host a Virtual Research Investor Event on Tuesday, April 9, 2024
GlobeNewswire Inc.
ADC Therapeutics Gewährt Zuschüsse an neue Mitarbeiter im Rahmen des Anreizplan
GlobeNewswire Inc.
ADC Therapeutics gibt Geschäftsergebnisse für das 4. Quartal und das Gesamtjahr 2023 sowie aktuelle Geschäftszahlen bekannt
GlobeNewswire Inc.
Adc Therapeutics SA Stock (ADCT) Financials Data
Adc Therapeutics SA (ADCT) Revenue 2024
ADCT reported a revenue (TTM) of $69.56 million for the quarter ending December 31, 2023, a -66.86% decline year-over-year.
Adc Therapeutics SA (ADCT) Net Income 2024
ADCT net income (TTM) was -$240.05 million for the quarter ending December 31, 2023, a -52.78% decrease year-over-year.
Adc Therapeutics SA (ADCT) Cash Flow 2024
ADCT recorded a free cash flow (TTM) of -$121.90 million for the quarter ending December 31, 2023, a +12.30% increase year-over-year.
Adc Therapeutics SA (ADCT) Earnings per Share 2024
ADCT earnings per share (TTM) was -$2.95 for the quarter ending December 31, 2023, a -46.77% decline year-over-year.
About Adc Therapeutics SA
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are ADCT-402, an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma; and ADCT-301, an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma, non-Hodgkin lymphoma, and solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 and ADCT-602, as well as preclinical product candidates, including ADCT-701 and ADCT-901. ADC Therapeutics SA has a collaboration and license agreement with Genmab A/S. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
2.49%
0.59%
Cap:
|
Volume (24h):